Search clinical trials for: BAY94-8862 (1.25mg)

Total 741 results

Bayer

Completed

Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

Heart Failure

Germany
Bayer

Completed

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)

Diabetic Nephropathies

Japan
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

Pharmacokinetics

Germany
Bayer

Completed

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR) (ReFineDR)

Diabetic Retinopathy

Korea, Republic of, Russian Federation, Hong Kong, Taiwan, United States, Argentina, Japan, Denmark, Israel, Spain, Sweden, China, Colombia, Italy, Portugal
Bayer

Completed

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN)

Diabetic Nephropathies

Hong Kong, Australia, Spain, Portugal, United States, France, Canada, Netherlands, Austria, Finland, Poland, Taiwan, Hungary, Israel, Italy, South Africa, Sweden, Bulgaria, Germany, Denmark, Czechia, Korea, Republic of, Norway
Bayer

Active, not recruiting

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD)

Non-diabetic Chronic Kidney Disease

Hong Kong, United States, Spain, China, Belgium, Taiwan, Australia, Korea, Republic of, Russian Federation, United Kingdom, Singapore, Malaysia, Japan, Greece, Israel, Hungary, Italy, Czechia, Denmark, Argentina, Bulgaria, Mexico, I... and more
Bayer

Completed

A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

Chronic Kidney Disease | Worsening Chronic Heart Failure

Germany
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

Pharmacokinetics

Germany
Bayer

Recruiting

A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Chronic Kidney Disease

India
Bayer

Recruiting

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States, Germany, Argentina, Belgium, Brazil, Canada, Chile, Colombia, France, Italy, Korea, Republic of, Luxembourg, Mexico, Netherlands, Russian Federation, Saudi Arabia, Singapore, Slovenia, Spain, Switzerland, Taiwan, Th... and more
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD)

Chronic Kidney Disease

Belgium, Finland, France, China, Hong Kong, Switzerland, United States, Turkey, Greece, New Zealand, Poland, South Africa, Spain, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, ... and more
Bayer

Completed

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR) (DeFineDR)

Diabetic Retinopathy

United Kingdom, Bulgaria
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD)

Diabetic Kidney Disease

Belgium, Finland, France, Spain, China, Hong Kong, Switzerland, United States, Colombia, Turkey, Greece, New Zealand, Poland, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, Sweden, Austr... and more
Bayer

Completed

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants (FIGARO-BM)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Spain, Belgium, United States, Russian Federation, Hong Kong, Singapore, Taiwan, Korea, Republic of, Canada, Austria, Italy, Japan, Denmark, Australia, Bulgaria, Czechia, Finland, Israel, Netherlands, Sweden, Portugal
Bayer

Recruiting

A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients (SMART-Finder)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Germany
Bayer

Recruiting

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria (FIONA)

Proteinuria | Chronic Kidney Disease

Switzerland, Belgium, Netherlands, United States, Australia, Turkey, Germany, United Kingdom, Austria, France, Hungary, Canada, Denmark, Italy, Korea, Republic of, Spain, Finland, Czechia, Sweden, Poland, Greece, Israel, China, Lithuania and more
Bayer

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (FIONA OLE)

Proteinuria | Chronic Kidney Disease | Children

Switzerland, Belgium, United States, Spain, Australia, United Kingdom, Argentina, Austria, Germany, Greece, Italy, France, Netherlands, Hungary, Canada, Finland, Sweden, Czechia, Poland, Turkey, Israel, Lithuania, Denmark, Korea, Republic... and more
Bayer

Active, not recruiting

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF)

Heart Failure

United States, Spain, Denmark, Korea, Republic of, Taiwan, Australia, Hong Kong, Russian Federation, Israel, Canada, Malaysia, United Kingdom, Latvia, Netherlands, Japan, Brazil, China, Lithuania, Poland, Turkey, Italy, Austria, Bul... and more
Bayer

Completed

A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

Diabetic Nephropathy | Worsening Chronic Heart Failure

Germany
JW Pharmaceutical

Completed

Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients

Hyperuricemia | Gout

Korea, Republic of
Bayer

Recruiting

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States, Belgium, Spain, Taiwan, Korea, Republic of, Netherlands, Japan, Italy, Denmark, Israel, Canada, France, India, Germany
Bayer

Completed

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Hemophilia A

United States
Bayer
University of California, San Francisco; Laboratorium für Klinische Forschung; Diagnostic Cytology Laboratory

Completed

Endometrial Safety Study

Postmenopause

Mexico, United States, Italy, Denmark, Austria, Argentina, Brazil, Russian Federation
Cingulate Therapeutics

Recruiting

Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301

ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit Hyperactivity

United States
Shaheer A. Khan
AstraZeneca; Melanoma Research Alliance

Completed

Intermittent Selumetinib for Uveal Melanoma

Uveal Melanoma

United States
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (T8)

Rheumatoid Arthritis

China
Bayer

Completed

BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease (ARTS)

Heart Failure

Denmark, Germany, Belgium, Austria, Czechia, Israel, Norway, Sweden, Poland, Finland
Pharmbio Korea Co., Ltd.

Recruiting

Study of PBK_L1704 for the Treatment of Moderate to Severe Acute Pain After Bunionectomy in South Korea

Acute Pain

Korea, Republic of
Bayer

Completed

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results (FLAMINGO)

Type 2 Diabetes | Chronic Kidney Disease

United States
Bayer

Completed

Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone (ARTS-HF Japan)

Heart Failure

Japan
GemVax & Kael

Recruiting

Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

Progressive Supranuclear Palsy

Korea, Republic of
Life Molecular Imaging SA

Completed

Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation

Neoplasms | Diagnostic Imaging

Korea, Republic of, United States, Germany
Life Molecular Imaging SA

Completed

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

Alzheimer Disease

United States, France, Japan, Australia, Germany
Life Molecular Imaging SA

Completed

Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients

Alzheimer Disease | Amyloid Beta-Protein

Australia
Life Molecular Imaging SA

Completed

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

Down Syndrome | Amyloid Beta-protein

United States
Jiangsu Nhwa Pharmaceutical Co., Ltd.

Recruiting

A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects

Schizophrenia

China
Bayer

Completed

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone (ARTS-HF)

Heart Failure

France, Taiwan, United States, Turkey, Spain, Greece, Portugal, Germany, Canada, Austria, Czechia, Denmark, Israel, Korea, Republic of, Poland, South Africa, Sweden, Bulgaria, Italy, Finland, Hungary, Lithuania, Netherlands, Australia, ...
GemVax & Kael

Active, not recruiting

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

Mild to Moderate Alzheimer's Disease

Spain, United States, Netherlands, Poland
GemVax & Kael

Recruiting

GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

Korea, Republic of
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Glioblastoma | High Grade Glioma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Linda Van Eldik
Duke Clinical Research Institute; Alzheimer's Association

Completed

A MAD Study of TT301/MW189 in Healthy Volunteers

Healthy Adult Volunteers

United States
Life Molecular Imaging SA

Completed

Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

Neoplasms

United States
Johns Hopkins University
National Institute on Aging (NIA)

Completed

Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment (MCI)

United States
Life Molecular Imaging SA

Completed

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

Alzheimer Disease | Amyloid Beta-Protein

United States, Switzerland, Australia, Germany, Japan
Bayer

Completed

Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

Oncology

United States
Bayer

Recruiting

An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions (FINEROD)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Germany, Japan
Merck Sharp & Dohme LLC

Completed

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Pulmonary Arterial Hypertension
Bayer

Completed

Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

Neoplasms

Japan
Chicago Headache Center & Research Institute

Recruiting

COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study (COACT)

Chronic Migraine, Headache

United States
Suzhou Alphamab Co., Ltd.
Novotech (Australia) Pty Limited

Recruiting

A Study to Evaluate Effects of KN056 in Healthy Participants

Type 2 Diabetes

New Zealand

3

Subscribe